529 related articles for article (PubMed ID: 8641482)
1. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
Suikkari AM; Tiitinen A; Stenman UH; Seppälä M; Laatikainen T
Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
[TBL] [Abstract][Full Text] [Related]
4. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
5. Women with clomiphene citrate resistant polycystic ovarian disease: predictors of spontaneous ovulation after laparoscopic ovarian drilling.
Abuelghar WM; Bayoumy HA; Ellaithy MI; Khalil MS
Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():178-85. PubMed ID: 24576485
[TBL] [Abstract][Full Text] [Related]
6. The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment.
Genazzani AD; Battaglia C; Gamba O; Petraglia F; Malavasi B; Genazzani AR
J Assist Reprod Genet; 2000 May; 17(5):269-75. PubMed ID: 10976414
[TBL] [Abstract][Full Text] [Related]
7. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
8. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
Siegberg R; Nilsson CG; Stenman UH; Widholm O
Fertil Steril; 1984 Jun; 41(6):888-93. PubMed ID: 6233177
[TBL] [Abstract][Full Text] [Related]
9. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
Moutos D; Smith S; Zacur H
Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome.
Timmerman-van Kessel EC; Cikot RJ; Dargel-Donkers EJ; Zwertbroek W; van Dop PA; Schoot DC
Fertil Steril; 2000 Jun; 73(6):1145-8. PubMed ID: 10856472
[TBL] [Abstract][Full Text] [Related]
11. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
Nappi C; Farace MJ; Leone F; Minutolo M; Tommaselli AP; Montemagno U
Eur J Obstet Gynecol Reprod Biol; 1987 Jul; 25(3):209-19. PubMed ID: 2956138
[TBL] [Abstract][Full Text] [Related]
12. Endocrine changes after laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovarian syndrome.
Al-Ojaimi EH
Saudi Med J; 2004 Aug; 25(8):1032-9. PubMed ID: 15322594
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor alpha versus LH and androstendione as a reliable predictor of spontaneous ovulation after laparoscopic ovarian drilling for women with clomiphene citrate resistance polycystic ovarian disease.
Seyam E; Hefzy E
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():126-133. PubMed ID: 29408743
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
Falsetti L; Galbignani E
Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
[TBL] [Abstract][Full Text] [Related]
15. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.
Anttila L; Koskinen P; Kaihola HL; Erkkola R; Irjala K; Ruutiainen K
Fertil Steril; 1992 Oct; 58(4):697-702. PubMed ID: 1426312
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
17. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use.
Castelo-Branco C; Martínez de Osaba MJ; Pons F; Fortuny A
Metabolism; 1997 Apr; 46(4):437-40. PubMed ID: 9109850
[TBL] [Abstract][Full Text] [Related]
19. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
[TBL] [Abstract][Full Text] [Related]
20. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.
Vercellini P; Trespidi L; Colombo A; Vendola N; Marchini M; Crosignani PG
Fertil Steril; 1993 Jul; 60(1):75-9. PubMed ID: 8513962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
